SG11202005719UA - Carbamate and urea compounds as multikinase inhibitors - Google Patents
Carbamate and urea compounds as multikinase inhibitorsInfo
- Publication number
- SG11202005719UA SG11202005719UA SG11202005719UA SG11202005719UA SG11202005719UA SG 11202005719U A SG11202005719U A SG 11202005719UA SG 11202005719U A SG11202005719U A SG 11202005719UA SG 11202005719U A SG11202005719U A SG 11202005719UA SG 11202005719U A SG11202005719U A SG 11202005719UA
- Authority
- SG
- Singapore
- Prior art keywords
- carbamate
- urea compounds
- multikinase inhibitors
- multikinase
- inhibitors
- Prior art date
Links
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 title 1
- 229940124303 multikinase inhibitor Drugs 0.000 title 1
- 150000003672 ureas Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762608375P | 2017-12-20 | 2017-12-20 | |
| PCT/US2018/064677 WO2019125798A1 (en) | 2017-12-20 | 2018-12-10 | Carbamate and urea compounds as multikinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005719UA true SG11202005719UA (en) | 2020-07-29 |
Family
ID=66994996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005719UA SG11202005719UA (en) | 2017-12-20 | 2018-12-10 | Carbamate and urea compounds as multikinase inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11358949B2 (zh) |
| EP (1) | EP3727364A4 (zh) |
| JP (1) | JP2021506885A (zh) |
| KR (1) | KR20200100120A (zh) |
| CN (1) | CN111511361A (zh) |
| AU (1) | AU2018388439B2 (zh) |
| CA (1) | CA3086522A1 (zh) |
| SG (1) | SG11202005719UA (zh) |
| TW (1) | TW201940473A (zh) |
| WO (1) | WO2019125798A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20200355A (es) * | 2018-01-26 | 2021-02-22 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
| JP7480048B2 (ja) | 2018-01-26 | 2024-05-09 | エグゼリクシス， インコーポレイテッド | キナーゼ依存的障害を処置するための化合物 |
| CA3088200A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| AR119069A1 (es) * | 2019-06-04 | 2021-11-24 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de quinasas |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2371383T3 (es) * | 2003-09-26 | 2011-12-30 | Exelixis, Inc. | N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer. |
| TW200803842A (en) * | 2005-11-04 | 2008-01-16 | Wyeth Corp | Antineoplastic combinations of temsirolimus and sunitinib malate |
| US20090227556A1 (en) | 2008-01-31 | 2009-09-10 | Eisai R&D Management Co., Ltd. | Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives |
| KR20130043198A (ko) * | 2010-07-16 | 2013-04-29 | 피라말 엔터프라이지즈 리미티드 | 키나제 억제제로서 치환된 이미다조퀴놀린 유도체 |
| WO2013032797A2 (en) * | 2011-08-26 | 2013-03-07 | New Hope R & D Bioscience, Inc. | Oxetane 3,3-dicarboxamide compounds and methods of making and using same |
| KR101909433B1 (ko) * | 2011-12-02 | 2018-10-18 | 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 | 키나제 저해제의 부작용 저감제 |
| US8993614B2 (en) * | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| US20170342033A1 (en) | 2015-06-29 | 2017-11-30 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| WO2017029362A1 (en) | 2015-08-19 | 2017-02-23 | Sandoz Ag | Asymmetric bisamidation of malonic ester derivatives |
| CA3010862A1 (en) * | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
-
2018
- 2018-12-10 TW TW107144377A patent/TW201940473A/zh unknown
- 2018-12-10 KR KR1020207020433A patent/KR20200100120A/ko not_active Application Discontinuation
- 2018-12-10 AU AU2018388439A patent/AU2018388439B2/en not_active Ceased
- 2018-12-10 CN CN201880082742.XA patent/CN111511361A/zh active Pending
- 2018-12-10 SG SG11202005719UA patent/SG11202005719UA/en unknown
- 2018-12-10 WO PCT/US2018/064677 patent/WO2019125798A1/en unknown
- 2018-12-10 CA CA3086522A patent/CA3086522A1/en not_active Abandoned
- 2018-12-10 US US16/770,697 patent/US11358949B2/en active Active
- 2018-12-10 JP JP2020534192A patent/JP2021506885A/ja active Pending
- 2018-12-10 EP EP18890797.6A patent/EP3727364A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021506885A (ja) | 2021-02-22 |
| AU2018388439A1 (en) | 2020-07-02 |
| AU2018388439B2 (en) | 2021-05-20 |
| CN111511361A (zh) | 2020-08-07 |
| CA3086522A1 (en) | 2019-06-27 |
| US11358949B2 (en) | 2022-06-14 |
| WO2019125798A1 (en) | 2019-06-27 |
| US20210163445A1 (en) | 2021-06-03 |
| KR20200100120A (ko) | 2020-08-25 |
| EP3727364A1 (en) | 2020-10-28 |
| TW201940473A (zh) | 2019-10-16 |
| EP3727364A4 (en) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271999A (en) | TYK2 inhibitors and uses thereof | |
| HK1249101A1 (zh) | 作為magl抑制劑的1，1，1-三氟-3-羥基丙-2-基氨基甲酸酯衍生物及1，1，1-三氟-4-羥基丁-2-基氨基甲酸酯衍生物 | |
| HK1256997A1 (zh) | Tyk2抑制劑及其用途 | |
| HK1248690A1 (zh) | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 | |
| IL248240B (en) | Compounds containing carbazole-amide, carbamate and urea, preparations containing them and their uses | |
| HK1249104A1 (zh) | 作為HDAC8抑制劑的α-肉桂酰胺化合物和組合物 | |
| IL291265A (en) | Selective jak1 inhibitors and their uses | |
| ZA201804624B (en) | Benzamide compounds and their use as herbicides | |
| SG11201708027XA (en) | Compounds and their use as bace1 inhibitors | |
| HK1249497A1 (zh) | Ebna1抑制劑及其使用方法 | |
| SI3538528T1 (sl) | Pirol amidi kot alfa v integrin inhibitorji | |
| SG11202005719UA (en) | Carbamate and urea compounds as multikinase inhibitors | |
| HK1251174A1 (zh) | 苯甲酰胺和活性化合物的組合物及其使用方法 | |
| HUE063120T2 (hu) | LRRC33-inhibitorok és alkalmazásuk | |
| ZA201704116B (en) | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase | |
| HK1248209A1 (zh) | 尿素衍生物和其用途 | |
| IL267238A (en) | The paranase inhibitors and their use | |
| KR102135648B9 (ko) | 항독성 또는 항병원성 활성을 갖는 레오이딘 화합물 및 이의 용도 | |
| EP3246314A4 (en) | Carbamate compound and use thereof | |
| EP3246319A4 (en) | Carbamate compound and use thereof | |
| EP3246312A4 (en) | Carbamate compound and use thereof | |
| IL261646A (en) | History of urea and amide and their use as cyclophilin inhibitors | |
| ZA201803212B (en) | Gelatinase inhibitors and use thereof | |
| IL291895A (en) | mcl1 inhibitors and their uses | |
| EP3246316A4 (en) | Carbamate compound and use thereof |